AbbVie Presents P-II Study (SLEek) Results of Rinvoq (upadacitinib) for the Treatment of Systemic Lupus Erythematosus at EULAR 2023
Shots:
- The P-II study evaluates upadacitinib (30mg) as monotx. & in combination with ABBV-599 high dose (elsubrutinib - 60mg & upadacitinib - 30mg) vs PBO in 341 patients
- The trial met its 1EPs of SLE responder index (SRI-4) & steroid dose ≤10mg prednisone equivalent once per day @24wk. vs PBO (54.8% & 48.5% vs 37.3%) & evaluate reductions in disease activity & glucocorticoid use. The trial met 2EPs at 48wk. in both active treatment groups, incl. lupus flares showed greater treatment effects in upadacitinib & ABBV-599
- Other measures of disease activity & treatment response were met, incl. BICLA response, SRI-4 & LLDAS with no new safety signals, rate of TEAEs (ABBV-599 at 86.8%, upadacitinib at 82.3%, PBO at 78.7%); SAEs (10.3% & 21.0% vs 17.3%)
Ref: PRNewswire | Image: AbbVie
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
